BG-136, an innate immune stimulator derived from Durvillaea Antarctica, activates both innate and adaptive immune cells within the tumor microenvironment (TME), thereby exerting broad-spectrum antitumor effects.

BG136, administered at 0.3 mg/kg intravenously twice a week, effectively inhibits tumor growth in a C57BL/6 J mouse colorectal cancer (CRC) cell line MC38 allograft tumor model, without causing weight loss. Additionally, when combined with an anti-PD1 antibody (200 μg per mouse, i.v. once a week) in the MC38 syngeneic tumor model, BG136 enhances the tumor inhibitory effect of the anti-PD1 antibody, leading to more effective suppression of tumor growth.